MC1R and X-linked lymphoproliferative disease: Dersimelagon (formerly MT‐7117) is a novel, synthetic, orally administered nonpeptide small molecule selective agonist for MC1R being investigated for the treatment of EPP, XLP, and diffuse cutaneous systemic sclerosis.